{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:37:51Z","timestamp":1769639871765,"version":"3.49.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.010","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T15:56:58Z","timestamp":1726329418000},"page":"123-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innovations in Cutaneous Lupus"],"prefix":"10.1016","volume":"43","author":[{"given":"Rachel R.","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton V.","family":"Warp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara A.","family":"Hartoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea D.","family":"Maderal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib2","first-page":"330","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica (Bucur)"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.annder.2020.08.052","article-title":"Lupus erythematosus: significance of dermatologic findings","volume":"148","author":"Lenormand","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2024.08.010_bib4","first-page":"236","article-title":"Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: two cases report","volume":"38","author":"Abdelmouttalib","year":"2021","journal-title":"Pan Afr Med J"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jaad.2015.12.029","article-title":"Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE)","volume":"74","author":"Tiao","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.010_bib6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/archderm.138.9.1175","article-title":"Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus","volume":"138","author":"Black","year":"2002","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib7","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.mayocp.2022.06.022","article-title":"Epidemiology of cutaneous lupus erythematosus among adults over four decades (1976-2018): a lupus midwest network (LUMEN) study","volume":"97","author":"Hocao\u011flu","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","article-title":"Incidence of\u00a0cutaneous lupus erythematosus, 1965-2005: a population-based study","volume":"145","author":"Durosaro","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2024.08.010_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/TCRM.S3193","article-title":"Topical calcineurin inhibitors in systemic lupus erythematosus","volume":"6","author":"Lampropoulos","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/BOR.0000000000000704","article-title":"Treatment of cutaneous lupus erythematosus: current approaches and future strategies","volume":"32","author":"Shi","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.010_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jamadermatol.2020.1698","article-title":"Creation and validation of classification criteria for discoid lupus erythematosus","volume":"156","author":"Elman","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2009.09472.x","article-title":"Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients","volume":"162","author":"Vera-Recabarren","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaad.2013.02.010","article-title":"Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus","volume":"69","author":"Merola","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.010_bib15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2230.2008.03138.x","article-title":"Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study","volume":"34","author":"Barikbin","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib16","doi-asserted-by":"crossref","first-page":"e14675","DOI":"10.1111\/dth.14675","article-title":"Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus","volume":"34","author":"Barua","year":"2021","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib17","first-page":"281","article-title":"Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy","volume":"25","author":"Roenigk","year":"1980","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bjd.17636","article-title":"Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus","volume":"180","author":"Ogunsanya","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","article-title":"The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment","volume":"11","author":"Luijten","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2020.1775928","article-title":"Which is the best SLE activity index for clinical trials?","volume":"31","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib22","doi-asserted-by":"crossref","first-page":"e000529","DOI":"10.1136\/lupus-2021-000529","article-title":"Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need","volume":"8","author":"Guo","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.det.2024.08.010_bib23","doi-asserted-by":"crossref","first-page":"968469","DOI":"10.3389\/fmed.2022.968469","article-title":"Cutaneous lupus erythematosus disease assessment: highlighting CLE outcome measures","volume":"9","author":"Gaffney","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.det.2024.08.010_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-022-00436-7","article-title":"Targeting toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib26","doi-asserted-by":"crossref","first-page":"e00842","DOI":"10.1002\/prp2.842","article-title":"Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8","volume":"9","author":"Port","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2606","article-title":"Applying modeling and simulations for rational dose selection of novel toll-like receptor 7\/8 inhibitor enpatoran for indications of high medical need","volume":"112","author":"Klopp-Schulze","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.det.2024.08.010_bib28","first-page":"A100","article-title":"PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design","volume":"9","author":"Ranganathan","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.det.2024.08.010_bib29","first-page":"L17","article-title":"Safety, tolerability, and Exploratory efficacy of afimetoran, a TLR7\/8 inhibitor, in patients with cutaneous lupus erythematosus: a phase 1b randomized, double-blind, placebo-controlled study","volume":"75","author":"Hosein","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.010_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/156802609789044407","article-title":"IRAK-4 inhibitors for inflammation","volume":"9","author":"Wang","year":"2009","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4049\/jimmunol.1600583","article-title":"Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity","volume":"198","author":"Dudhgaonkar","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib32","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid dendritic cell biology and its role in immune-mediated diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin Transl Immunology"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"11","key":"10.1016\/j.det.2024.08.010_bib34","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib35","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1084\/jem.194.12.f59","article-title":"A\u00a0pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus","volume":"194","author":"R\u00f6nnblom","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.det.2024.08.010_bib37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of\u00a0anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"595","key":"10.1016\/j.det.2024.08.010_bib39","doi-asserted-by":"crossref","first-page":"eabf8442","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib40","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib41","doi-asserted-by":"crossref","first-page":"e000424","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"10381","key":"10.1016\/j.det.2024.08.010_bib43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"SUPPL 1","key":"10.1016\/j.det.2024.08.010_bib44","first-page":"27","article-title":"Successful treatment of cutaneous lupus erythematosus with tofacitinib","volume":"183","author":"Ananthan","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.08.010_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","article-title":"Oral tofacitinib citrate for recalcitrant cutaneous lupus","volume":"20","author":"Bonnardeaux","year":"2022","journal-title":"JAAD Case Reports"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib46","first-page":"425","article-title":"Open-label phase 2 pilot study of oral tofacitinib in adult subjects with discoid lupus erythematosus (DLE)","volume":"22","author":"Alsukait","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib47","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.det.2024.08.010_bib48","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2147\/CCID.S419344","article-title":"Treatment of discoid lupus erythematosus with upadacitinib: a case report","volume":"16","author":"Hu","year":"2023","journal-title":"Clin Cosmet Invest Dermatol"},{"issue":"17","key":"10.1016\/j.det.2024.08.010_bib49","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib53","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.det.2024.08.010_bib55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib56","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A\u00a0randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib58","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"The Lancet Rheumatology"},{"issue":"10","key":"10.1016\/j.det.2024.08.010_bib59","doi-asserted-by":"crossref","first-page":"e2338200","DOI":"10.1001\/jamanetworkopen.2023.38200","article-title":"Anifrolumab for adolescent discoid lupus erythematosus","volume":"6","author":"Shaw","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib60","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10155","key":"10.1016\/j.det.2024.08.010_bib62","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.det.2024.08.010_bib65","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"Van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2024.08.010_bib66","doi-asserted-by":"crossref","first-page":"915828","DOI":"10.3389\/fmed.2022.915828","article-title":"Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus","volume":"9","author":"Fetter","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14728214.2023.2273536","article-title":"Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials","volume":"28","author":"Lim","year":"2023","journal-title":"Expet Opin Emerg Drugs"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib68","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib69","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.39085","article-title":"Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus","volume":"67","author":"Vital","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.010_bib70","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0961203313497115","article-title":"Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature","volume":"22","author":"Hofmann","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.det.2024.08.010_bib71","doi-asserted-by":"crossref","first-page":"1159794","DOI":"10.3389\/fmed.2023.1159794","article-title":"Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review","volume":"10","author":"Sans-Pola","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib72","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jaad.2020.05.058","article-title":"Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients","volume":"83","author":"Salle","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib73","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.det.2024.08.010_bib75","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht","year":"2017","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.08.010_bib77","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.jaut.2021.102707","article-title":"Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus","volume":"123","author":"Lu","year":"2021","journal-title":"J\u00a0Autoimmun"},{"issue":"14","key":"10.1016\/j.det.2024.08.010_bib78","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0961203316655215","article-title":"Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus","volume":"25","author":"Schwarting","year":"2016","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.det.2024.08.010_bib79","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib80","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.berh.2020.101485","article-title":"Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sj\u00f6gren's syndrome","volume":"34","author":"van den Hoogen","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.det.2024.08.010_bib82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2021.09.024","article-title":"Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies","volume":"335","author":"Lutgens","year":"2021","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.det.2024.08.010_bib83","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S2665-9913(20)30038-2","article-title":"Rationale for CD40 pathway blockade in autoimmune rheumatic disorders","volume":"2","author":"Pucino","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.det.2024.08.010_bib84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fmed.2020.00498","article-title":"Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab","volume":"7","author":"Hassan","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.det.2024.08.010_bib85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging b-cell therapies in systemic lupus erythematosus","volume":"17","author":"Bag-Ozbek","year":"2021","journal-title":"Therapeut Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-020-00405-2","article-title":"Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline","volume":"34","author":"Klavdianou","year":"2020","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.det.2024.08.010_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/25785826.2019.1698929","article-title":"B\u00a0cells targeting therapy in the management of systemic lupus erythematosus","volume":"43","author":"Lee","year":"2020","journal-title":"Immunological Medicine"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib88","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib89","doi-asserted-by":"crossref","first-page":"e1428158","DOI":"10.1080\/2162402X.2018.1428158","article-title":"Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)","volume":"7","author":"Elias","year":"2018","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.det.2024.08.010_bib90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","article-title":"Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis","volume":"32","author":"Narain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.det.2024.08.010_bib91","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?","volume":"61","author":"Reddy","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.det.2024.08.010_bib92","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.010_bib93","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2024.08.010_bib94","first-page":"419029","article-title":"The pathology of T cells in systemic lupus erythematosus","volume":"2014","author":"Mak","year":"2014","journal-title":"J\u00a0Immunol Res"},{"issue":"4","key":"10.1016\/j.det.2024.08.010_bib95","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J\u00a0Pathol"},{"issue":"11","key":"10.1016\/j.det.2024.08.010_bib96","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.det.2024.08.010_bib97","doi-asserted-by":"crossref","first-page":"e003317","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.det.2024.08.010_bib98","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.det.2024.08.010_bib99","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/d41573-023-00166-x","article-title":"CAR T cell therapies raise hopes - and questions - for lupus and autoimmune disease","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:04:35Z","timestamp":1755695075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000822"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in Cutaneous Lupus","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}